April 2015

		Fund			S&P500 Index	
		Performance	Inception to Date		Performance	Inception to Date
2005		+14.01%	+14.01%		+4.78%	+4.78%
2006		+16.91%	+33.29%		+13.62%	+19.05%
2007		+4.06%	+38.70%		+3.53%	+23.25%
2008		-47.99%	-27.86%		-38.49%	-24.18%
2009		+42.74%	+2.97%		+23.45%	-6.40%
2010		+24.94%	+28.65%		+12.78%	+5.57%
2011		+1.79%	+30.96%		0.00%	+5.56%
2012		+24.17%	+62.61%		+13.41%	+19.71%
2013		+42.96%	+132.46%		+29.60%	+55.15%
2014		+3.92%	+141.59%		+11.39%	+72.82%
	MTD	YTD		MTD	YTD	
Jan 2015	-2.59%	-2.59%	+135.32%	-3.10%	-3.10%	+67.46%
Feb 2015	+3.53%	+0.84%	+143.63%	+5.49%	+2.21%	+76.65%
Mar 2015	+0.99%	+1.84%	+146.03%	-1.74%	+0.44%	+73.58%
Apr 2015	-1.96%	-0.15%	+141.22%	+0.85%	+1.29%	+75.06%
		1		1		

In April, the Fund fell by 1.96%, while the S&P500 rose by 0.85%. We fell by a similar amount to all the smaller cap indices which have, like us, also relinquished their gains for the year to date.

The month saw a return to the Nifty Fifty conditions of last year, with large cap technology pulling up the S&P500. Within the overall market, growth had the better of it, as doubts returned about the strength of the recovery. Small cap value, the long-term outperforming sector, and therefore our preferred home, was the worst place to be.

However, while all that sounds pretty miserable, all is not lost, and our first quarter earnings have been coming in well. In this respect, we have many stocks, such as banks, where earnings may be 15% higher than a year ago and yet stock prices are little changed. We're also not completely sidelined in that as late as April 28th we were up 0.7%, at a new high, and doing fine against the indices.

This reprise of last year's conditions worries me less, as we are now keeping up generally, showing the ability to make progress when the sun is shining and our valuations are steadily improving as time goes by. We have some growth stocks in health care, such as drug chains and distributors, and the sell-off that got us at month-end does not feel serious.

Risk Warnings and Other Important Information

This document is issued by De Lisle Partners LLP, registered in England No.OC310994, authorised and regulated by the Financial Conduct Authority. The registered office of Valu-Trac Investment Management Ltd is Suite 150-153, 2nd Floor Temple Chambers, Temple Avenue, London, EC4Y 0DA, Head Office at Mains of Orton, Orton, Fochabers, Moray, Scotland IV32 7QE.

The Fund qualifies as an Undertaking for Collective Investment in Transferable Securities (UCITSIII).

This document should not be construed as investment advice or an offer to invest in the Fund. Nor should its content be interpreted as investment or tax advice for which you should consult your independent financial adviser and/or accountant. The information and opinion it contains have been compiled or arrived at from sources believed to be reliable at the time and are given in good faith, but no representation is made as to their accuracy, completeness or correctness. Any opinion expressed in this document represents the views of De Lisle Partners at the time of preparation, but is subject to change. For professional use only.

The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested. Past performance should not be viewed as a guide to future performance. Please read the Prospectus before making an investment.